Email Updates

Search form

You are here

Track the Research

Today's PrEP research agenda seeks to clarify how to deliver what's available—and identify new strategies

PrEP research today spans implementation research on delivering daily oral tenofovir-based PrEP and clinical trials of new agents, including vaginal ARV-containing rings and long-acting injectables.

There are many moving pieces and many product types.

One key advocacy message is that no single PrEP option—and no single prevention option—is right for all people, or for any one person all the time. We need to ensure that demonstration projects tell us how deliver what's available, and that research continues for additional options.

To learn more see: